Frost & Sullivan Applauds IRIS for Innovation in Diabetic Retinopathy Technology
By broadening exam access via seamless cloud-based technology, IRIS is enabling more physicians to identify patients at risk of blindness
MOUNTAIN VIEW, Calif., Feb. 2, 2016 /PRNewswire/ — Based on its recent analysis of the diabetic retinopathy market, Frost & Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with the 2015 North America Frost & Sullivan Award for New Product Innovation. IRIS, a prominent cloud-based retinal exam technology provider in North America, is poised to set the new industry standard in the rapidly growing diabetic retinopathy market. The IRIS technology presents superior price-performance value through products designed for diverse therapeutic applications, while aiding an improved, yet simplified, exam.
IRIS is seeking to transform the market by offering an end-to-end screening solution for primary care providers to rapidly identify patients with diabetic retinopathy. The technology was developed with an affordable, integrated software solution that not only facilitates early detection but also enhances patient care.
“The IRIS technology can both assess and detect the presence of micro aneurysms at the back of the eye, one of the first signs of diabetic retinopathy,” said Frost & Sullivan Research Analyst Swathi Allada. “The retinal imaging system, along with telemedicine, offers numerous advantages such as timely intervention, better treatment outcomes and elimination of the need for a non-physician eye care professional.”
The only FDA-approved, telemedicine solution for diabetic retinopathy
IRIS features a fully automated, affordable, non-mydriatic fundus camera, which requires minimal training for operation. The IRIS technology is the only Food and Drug Administration (FDA)-cleared, class II device indicated for use as a telemedicine platform to screen patients for diabetic retinopathy, macular edema, glaucoma and other suspected conditions….
Source: PR Newswire